You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)與密西根大學達成協議獲得基於PROTACs技術的MDM2蛋白降解劑獨家許可
格隆匯 11-30 08:06

格隆匯 11 月 30日丨亞盛醫藥-B(06855.HK)發佈公告,公司與密西根大學達成協議,將獲得一項基於蛋白降解靶向嵌合體(Proteolysis-Targeting Chimeras, PROTACs)技術開發的MDM2蛋白降解劑的全球獨家權益。該臨牀候選物已進入IND申報試驗階段。

根據披露,MDM2是腫瘤抑制因子p53的關鍵負調節因子,是迄今為止發現的最強的凋亡抑制因子之一,在腫瘤中高表達,對腫瘤的發生和發展起到重要的作用。PROTACs技術是通過泛素—蛋白酶體系統(UPS)誘導靶向蛋白降解的一種全新技術。此技術自問世以來受到來自學術界和業界的廣泛關注。區別於傳統的佔據驅動(occupancy-driven)的藥理學原理,事件驅動(event-driven)的PROTACs技術具有諸多優勢,比如具有高活性、高選擇性,催化降解作用模式,靶向不可成藥靶點等。

亞盛醫藥共同創始人兼首席科學顧問、密西根大學Warner-Lambert/Parke-Davis醫學教授、內科教授、藥理學教授和藥物化學專業教授、密西根醫療創新中心主任王少萌博士是這一研發領域的領軍人物。王少萌教授課題組通過運用PROTACs技術,對他們之前開發的MDM2抑制劑進行系統的構效關係研究,獲得了能夠有效誘導MDM2快速降解的高效MDM2降解劑。MDM2降解劑可以在小鼠異種移植的腫瘤模型中完全並持久地抑制腫瘤的生長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account